



Corporate Presentation

July 7, 2020



Forward looking statements

This presentation contains "forward-looking statements" as that term is defined in Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this presentation which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. These forward-looking statements generally can be identified by phrases such as Q BioMed, Inc. ("QBIO") or its management "believes," "expects," "anticipates," "foresees," "forecasts," "estimates" or other words or phrases of similar importance.

Such forward-looking statements include, among other things, the development, costs and results of new business opportunities. Actual results could differ from those projected in these forward-looking statements which are made as of the date of this presentation, and we assume no obligation to update any forward-looking statements. Our actual results may differ materially from those stated or implied in such forward-looking statements, due to risks and uncertainties associated with our business, which include the risk factors disclosed in our public filings. Although we believe that any beliefs, plans, expectations and intentions contained in this presentation are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should review all of the information set forth herein and should also understand the risk factors and the inherent uncertainties associated with new business opportunities and development stage. Any use of this information for any purpose other than in connection with the consideration of an investment in Q BioMed Inc. may subject the user to criminal and civil liability.

This presentation does not constitute an offer to sell any securities or the solicitation of an offer to sell any securities by Q BioMed Inc.



Corporate Introduction





Rapid biotech growth has created a plethora of scientific assets. And with so many assets being developed so quickly, things fall by the wayside... even if they shouldn't.

That's the cost of innovation.



At Q BioMed, we find
undiscovered or undervalued
biomedical technologies and
maximize their potential yield.
That's the opportunity

Oncology

strontium⁸⁹
Strontium Chloride Sr-89
Injection, USP

METASTRON

UTTROSIDE-B

Ophthalmology

MAN 01

MAN 11

GDF15

Rare Disease

QBM-001

UTTROSIDE-B

Infectious & Vascular
Diseases

MAN 19

MAN 12

This is our growing portfolio
of high-value assets



Drug Candidate | Preclinical | Phase 1 | Phase 2 | Phase 3 | Approval



Radiopharmaceutical for metastatic bone cancer pain

QBM-001

Pediatric non-verbal Autism Spectrum Disorder

UTTROSIDE-B

Chemotherapeutic for liver cancer

MAN 19

Infectious diseases (including COVID-19)

MAN 01

Topical eyedrops for glaucoma

MAN 11

Biologic Long Lasting Injection for Glaucoma

MAN 12

Acute Kidney disease





Our leading commercial asset is

strontium⁸⁹

Strontium Chloride Sr-89
Injection, USP

CMO received final FDA approval - Nov, 2019
Full ramp-up and sales delivered - Q2, 2020



The market unmet need: bone mets and pain

- The majority of patients with bone metastases develop severe pain as their disease progresses, resulting in a considerable reduction in their QoL
 - ~ 75% of patients with bone mets complain of pain as their main symptom and the dominant reason for a decreased QoL¹
 - Appropriate pain management may be difficult, particularly in the case of poorly localized discomfort²
- A multidisciplinary approach to symptom palliation is recommended, with the aim of individualized treatment being “to add life to the years, not years to the life”
- Analgesic drugs, surgical interventions, local external-beam radiation therapy, and radiopharmaceutical therapies called ‘radionuclides’ have been developed and utilized for the systemic palliation of bone pain with more multilocular skeletal involvement

1. Tannock I, Gospodarowicz M, Meakin W, Panzarella T, Stewart L, Rider W. Treatment of metastatic cancer with low-dose prednisone: evaluation of pain and quality of life as pragmatic indices of response. *J Clin Oncol.* 1989;7:590-597.

2. Wagner G. Frequency of pain in patients with cancer. *Recent Results Cancer Res.* 1984;89:64-71.



Bone mets - a worldwide market opportunity




10 Million

The number of people worldwide that experience daily pain due to malignant disease¹



75,000

The projected number of annual Sr-89 doses based on 0.5% of the market - 50,000 patients at 1.5 doses



8.4 Percent

The approximate CAGR at which the global bone metastasis market is expected to grow²

1. World Health Organization. Cancer pain relief and palliative care. World Health Organ Tech Rep Ser. 1990;804:7-73

2. Medgadget

Privileged and confidential information of Q BioMed Inc; do not distribute.

Strontium89 - a solution for many




Today:

- FDA approved for bone mets pain palliation
- NDA and ANDA held by Q BioMed
 - Operationalizing radiopharmaceuticals is highly complex, creating a high barrier to generic entry
- Global market authorizations held for METASTRON in 22 countries
- Commercially available as of Feb, 2020
- Medicare/payor reimbursed


In the future:

- Phase 4 clinical program planned to expand label to include overall survival (OS)
- Potential revenue \$200M+ in Yr1 post clinical trial

Strontium89 offers lasting pain relief and fewer new pain sites



Pre-treatment



5 months post-treatment

Potential for therapeutic indication

A decrease of >50% in serum PSAV was observed in 37% of patients with hormone-refractory prostate cancer after treatment with METASTRON™⁶

In a multicenter, RCT involving 126 patients with mCRPC, all of whom received external beam radiotherapy, additional treatment with METASTRON™ delayed disease progression [Porter_1993]

Many patients show a reduced intensity of hot spots on bone scan compared with pretreatment images.^{11,16} suggesting a possible tumoricidal effect from METASTRON™

Case reports describe regression of osteoblastic and osteolytic bone metastases in patients with breast cancer and hepatocellular carcinoma after treatment with METASTRON™^{16,17}

In the recent TRAPEZE randomized controlled trial of the clinical effectiveness and cost-effectiveness of chemotherapy with zoledronic acid (ZA), METASTRON, or both in men with bony metastatic castration-refractory prostate cancer, METASTRON was shown to improve CPFS, while ZA did not.

A potential survival benefit associated with the use of Sr-89 has been reported, and future randomized, placebo-controlled studies may confirm the effect of Sr-89 on overall survival



Mannin Research





Mannin
RESEARCH

MAN-19


Pharmaceutical: **MAN-19 Biologic**

Condition: **COVID-19**

Addressable Market: **Global Infectious Diseases**

Technology Partner: **Mannin**
RESEARCH

Stage: **Preclinical (Phase 1 Jan 2021)**



MAN-19 Stabilizes Endothelial Vasculature, Which May Have Beneficial Effects in Lung Injury and ARDS Associated With COVID-19

The vascular endothelium: the cornerstone of organ dysfunction in severe SARS-CoV-2 infection

Stéphanie Pons^{1,2}, Sofiane Fodil³, Elie Azoulay³ and Lara Zafrani^{1,3*}

EDITORIAL



Covid-19, Angiogenesis, and ARDS Endotypes

Lida Hariri, M.D., Ph.D., and C. Corey Hardin, M.D., Ph.D.

THE NEW ENGLAND JOURNAL OF MEDICINE

ORIGINAL ARTICLE

Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19

Maximilian Ackermann, M.D., Stijn E. Verleden, Ph.D., Mark Kuehnel, Ph.D., Axel Haverich, M.D., Tobias Welte, M.D., Florian Laenger, M.D., Arno Vanstapel, Ph.D., Christopher Werlein, M.D., Helge Stark, Ph.D., Alexandar Tzankov, M.D., William W. Li, M.D., Vincent W. Li, M.D., Steven I. Mentzer, M.D., and Danny Ioniok, M.D.

Plasma Angiotensin-converting Enzyme-2 Predicts the Onset of Acute Lung Injury in Critically Ill Patients

Ashish Agrawal¹, Michael A. Matthay^{2,3,4}, Kirsten N. Kangelaris⁵, John Stein⁶, Jeffrey C. Chu¹, Brandon M. Inge⁷, Alfredo Cortez⁸, Jason Abbott⁹, Kathleen D. Liu¹⁰, and Carolyn S. Calfee^{2,3}

¹School of Medicine, ²Department of Anesthesia, ³Department of Medicine, ⁴Cardiovascular Research Institute, and ⁵Department of Emergency Medicine, ⁶University of Pittsburgh, ⁷University of Pittsburgh, ⁸University of Pittsburgh, ⁹University of Pittsburgh, ¹⁰University of Pittsburgh

○ **MAN-19 is a first-in-class biologic treatment for COVID-19 patients, designed to ameliorate virus-induced pneumonia, sepsis and ARDS, decrease need of a ventilator, and reduced mortality rate. Half of deaths from COVID-19 related to vascular endothelial complications.**

○ **MAN-19 reduces vascular leakage, inflammation and coagulation by restoring vascular endothelial barrier integrity - a first endothelial host-directed solution to COVID-19.**

○ **Reducing endothelial permeability and vascular leakage in lung improves survival from severe influenza, supporting the host-directed therapeutic target for COVID-19 and other viruses likely to emerge in the future.**

○ **Potential in other viral infections and diseases, including: viral hemorrhagic fevers (Ebola, Dengue and Hantavirus), sepsis, severe influenza, malaria, anthrax, chronic mycobacterial infection, and corona viruses such as COVID-19.**



COVID-19 Clinical Program late 2020

- Mannin received up to \$7.7 million in Europe, which will fund 65 percent of every dollar incurred to advance a portfolio of therapeutic assets for vascular diseases currently in development including: COVID-19, other infectious diseases such as influenza, cardiovascular diseases, acute kidney diseases.
- Rapidly accelerating the time to the first clinical milestone for MAN-19. Supported by the Canadian government.
- An Investigational New Drug (IND) application (or similar clinical trial proposal) to regulators are planned for late 2020.
- MAN-19 therapeutic is virus-agnostic, which makes it relevant to other viral diseases today like influenza and future viral pandemic outbreaks.
- Therefore, a successful infectious disease application in COVID-19 would position MAN-19 very well as a potential government stockpile drug for inevitable future pandemics.
- Furthermore, a successful proof-of-concept clinical trial with MAN-19 in COVID-19 patients would provide the clinical dataset to quickly support the development of therapeutics for other vascular diseases such as sepsis, acute kidney injury, and of course glaucoma. All of these are very large markets with significant potential.




MAN-01

Pharmaceutical: **MAN-01 Topical Drops**

Condition: **Primary Open-Angle Glaucoma**

Addressable Market: **60 million patients worldwide**

Technology Partner: 

Stage: **Preclinical**





GDF15

Biomarker & Companion
Diagnostic:

GDF15

Condition:

Monitoring Glaucomatous Neurodegeneration

Addressable Market:

60 million

Technology Partner:

Washington University in St. Louis

Stage:

**Preclinical Development of Diagnostic Kit;
Clinical Trials using GDF15 as biomarker**





Rare Disease Assets





UTTROSIDE-B

Chemotherapy: **UTTROCIDE-B**

Condition: **Liver Cancer**

Addressable Market: **700,000 diagnoses/year**

Technology Partner: **Oklahoma Medical Research Foundation**

Stage: **Preclinical**





Q**B****M**-001

Pharmaceutical: **QBM-001 sprinkle formulation**

Condition: **Rare Pediatric Non-Verbal Disorder**

Addressable Market: **50,000 cases worldwide
15,000 in US alone**

Stage: **Pre-IND 505(b)2**

Pharmaceutical: **QBM-001 sprinkle formulation**





Capital Markets Overview and Management Outlook



Capital Markets

Shares Outstanding	22,200,000	Market Cap	\$35M
Warrants	8,8M	Ave Price	\$3.50
Inside Ownership	25%	Avg. Volume 30 day	100,000
Float	~ 14,000,000	Year end	November 30

3-Month
Trading History
Price **\$1.70**

As of Jun 15 2020



What to expect from us

Sales LAUNCH - Revenue generation expected in Q3 2020

Ph4 Post Marketing Study for Expanded Therapeutic Label Q4 21

Revenue in 2020

MAN-19 Infectious Diseases – COVID-19 Clinical Trial

IND Filing, Q4 2020

1 to 2-month Ph1 Clinical Trial Initiation Q1 2021

Uttroside-B – Liver Cancer

Complete pre-clinical and Prepare IND Q4 2020

Proof of Concept Studies H2 2021

MAN-01

Complete Molecule Optimization (Eye Drop)

Initiate Pre-IND Studies 2H2020 – Clinical Trial IND Q42020 – Clin Trial 2021

Additional Indications Formalized 2020

Pharma Partnership opportunities

Potential up-list to national exchange in H2 2020



Thank you

